Ellipsis Health
Voice AI platform that analyzes speech signals to support behavioral-health screening, symptom-severity measurement, and care-management prioritization.
Last updated: June 13, 2026
Back to directoryVoice biomarker platform that analyzes speech to generate behavioral and cognitive decision-support signals for clinicians, payers, call centers, and research workflows.
Organizations that want supervised screening or monitoring signals from speech for behavioral health, cognitive health, wellness, call-center, or clinical-trial workflows.
Compare within workflow: Patient access, triage, and agents · comparison shortlist · source index
Product-specific review. These product-specific signals summarize what the cited sources imply before treating Canary Speech as safe for a local clinical, operational, or research workflow.
| Regulatory / FDA | Treat as high-impact screening and clinical decision-support software. Confirm the intended-use boundary for each vocal biomarker, whether local deployment triggers medical-device, CDS, behavioral-health, employment, or trial-endpoint obligations, and who owns final clinical interpretation. |
|---|---|
| Privacy | Review consent, audio recording, survey data, identifiers, device metadata, de-identification, model-improvement rights, service providers, international transfers, retention, access controls, audit logs, BAA terms, and whether public privacy language matches the customer agreement. |
| Evidence | Require condition-specific validation for the exact population, language, device, setting, and workflow; review sensitivity, specificity, calibration, subgroup performance, background-noise robustness, and evidence behind any outcome or early-detection claims. |
| Workflow | Best governed as a supervised screening signal that routes uncertain or high-risk results to qualified staff, documents limits, avoids standalone diagnosis, and monitors false positives, missed cases, escalation quality, and patient experience after launch. |
Canary Speech describes patented vocal biomarker technology that uses machine learning to analyze short speech samples for behavioral, cognitive, wellness, and safety signals. Public materials position the product as clinical decision support across providers, payers, call centers, clinical trials, mobile apps, and APIs; FAQ materials describe acoustic, prosodic, and linguistic features, 20-40 second audio samples, model training from diagnosed and control populations, and published sensitivity and specificity examples for anxiety. Security and privacy pages describe HIPAA-aligned handling, de-identified research data, encryption in transit and at rest, third-party audits, HITRUST e1, ISO/IEC 27001, ISO/IEC 42001, and collection of survey responses or recorded audio that buyers should verify contractually.
Not for: Autonomous diagnosis, emergency triage, treatment decisions, workforce surveillance without governance, or patient-facing use without consent, equity, validation, privacy, and escalation review.
Use these links to confirm current claims, terms, regulatory status, pricing, and deployment requirements.